Triple Therapy for Postoperative Nausea and Vomiting in Laparoscopic Gastrointestinal Surgery
Status:
Recruiting
Trial end date:
2023-12-30
Target enrollment:
Participant gender:
Summary
Postoperative nausea and vomiting (PONV) are common in patients, especially in patients at
high risk. PONV may result in prolonged hospital stay and threaten patients' life. Because
the etiology of PONV is very complex, there is an increasing focus on combining antiemetics
from different classes for PONV prophylaxis. Fosaprepitant is a neurokinin-1 (NK-1) receptor
antagonist to prevent PONV. Palonosteron is a 5-HT3 receptor antagonist with high efficacy
and sustained action for PONV prophylaxis. Dexamethasone belongs to corticosteroid and also
has the ability to reduce the incident of PONV. This study aims to use the combination of
these three drugs in high-risk patients to test whether triple therapy is better than
combination of palonosteron and dexamethasone to prevent PONV.